News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Mehmet Ali Nahit Sendur

Articles by Mehmet Ali Nahit Sendur

TPS 38 ELCIN: Elacestrant in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: An Open-Label, Multicenter, Phase 2 Study

ByVirginia Kaklamani, MD, DSc,Giorgi Dzagnidze,Nicoleta Zenovia Antone,Anu Thummala,Mikheil Janjalia,Patricia Santi,Carlos Barrios,Mehmet Ali Nahit Sendur,Xiaoling Zhang,Angela Gambioli,Manuel Dominguez,Kathy Puyana Theall,Tomer Wasserman,William J. Gradishar, MD

June 12th 2025

Latest Updated Articles

Trending on CancerNetwork

FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma

Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer

The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?

Invasive Lobular Carcinoma: Diagnosis, Trials and What's Changing

Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma